Holdings of TCG Crossover Management, LLC
46 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 62.5 % of the equity sleeve
Sector breakdown
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
The quoted currency of each line, as declared.
Country breakdown
- US 77.7 %
- FR 21.2 %
- BE 0.6 %
- GB 0.5 %
Shares computed on the equity sleeve.
| Country | Lines | Value | Share |
|---|
| US | 43 | 2.6B $ | 77.71 % |
| FR | 1 | 721.7M $ | 21.19 % |
| BE | 1 | 21.5M $ | 0.63 % |
| GB | 1 | 16M $ | 0.47 % |
Positions
| Company | Shares | Value | Weight |
|---|
| Abivax SA | 6,481,085 | 721.7M $ | |
| CG oncology Inc | 3,670,206 | 248.4M $ | |
| Tango Therapeutics Inc | 10,531,071 | 220.3M $ | |
| Cogent Biosciences Inc | 4,946,894 | 190.4M $ | |
| CENTESSA PHARMACEUTICALS PLC | 4,286,480 | 170.3M $ | |
| Dianthus Therapeutics Inc | 1,676,624 | 140.7M $ | |
| Tyra Biosciences Inc | 3,248,980 | 124.4M $ | |
| Immunovant Inc | 4,457,988 | 110.7M $ | |
| BioCryst Pharmaceuticals Inc | 11,020,968 | 104.9M $ | |
| Mirum Pharmaceuticals Inc | 1,062,049 | 98.1M $ | |
| Vor BioPharma Inc | 5,673,078 | 96.5M $ | |
| Spyre Therapeutics Inc | 1,900,582 | 95.9M $ | |
| Amylyx Pharmaceuticals Inc | 6,243,812 | 86.8M $ | |
| Disc Medicine Inc | 1,341,862 | 85.8M $ | |
| Dyne Therapeutics Inc | 4,615,144 | 83.7M $ | |
| Monte Rosa Therapeutics Inc | 4,622,151 | 76M $ | |
| Savara Inc | 12,362,205 | 67.5M $ | |
| Revolution Medicines Inc | 576,473 | 56.1M $ | |
| Kodiak Sciences Inc | 1,445,538 | 55.1M $ | |
| LB Pharmaceuticals Inc | 1,839,489 | 45.3M $ | |
| Surrozen Inc | 1,473,101 | 42.9M $ | |
| Relay Therapeutics Inc | 4,273,356 | 42.5M $ | |
| Fulcrum Therapeutics Inc | 5,250,000 | 40.3M $ | |
| Century Therapeutics Inc | 17,754,430 | 39M $ | |
| Tectonic Therapeutic Inc | 1,204,891 | 37.2M $ | |
| Perspective Therapeutics Inc | 7,915,567 | 33M $ | |
| Xencor Inc | 2,452,138 | 29.6M $ | |
| Entrada Therapeutics Inc | 2,287,500 | 28.9M $ | |
| ALX Oncology Holdings Inc | 13,011,849 | 26.1M $ | |
| Arvinas Inc | 2,387,461 | 25.3M $ | |
| Janux Therapeutics Inc | 1,789,617 | 24.9M $ | |
| AGOMAB THERAPEUTICS SA | 2,053,233 | 21.5M $ | |
| Alector Inc | 10,000,000 | 21.5M $ | |
| MBX Biosciences Inc | 650,000 | 19.4M $ | |
| Silence Therapeutics PLC | 3,033,560 | 16M $ | |
| Liquidia Corp | 403,048 | 15.2M $ | |
| Ocular Therapeutix Inc | 1,647,752 | 14M $ | |
| AVALO THERAPEUTICS INC | 738,383 | 11M $ | |
| Monopar Therapeutics Inc | 132,103 | 7.2M $ | |
| Context Therapeutics Inc | 2,682,696 | 7M $ | |
| Structure Therapeutics Inc | 140,411 | 6.8M $ | |
| Cullinan Therapeutics Inc | 406,786 | 5.8M $ | |
| Korro Bio Inc | 416,301 | 4.7M $ | |
| LeonaBio Inc | 464,398 | 4.7M $ | |
| Upstream Bio Inc | 181,063 | 1.6M $ | |
| VISTAGEN THERAPEUTICS INC | 2,676,580 | 1.5M $ | |